2.1. Participants
Δ9-THC, mood disorders
AIDS
The participants in this study were recruited from the University of Northern Colorado and nearby communities. A total sample size of 28 participants was included in the current investigation. To be included, participants had to meet the following self-reported inclusion criteria: 18–50 years old, abstained from cannabis (Δ9-THC and/or CBD) for six weeks, and have no history of chronic alcohol and/or drug use. Participants were excluded if they were diagnosed with cardiovascular, neurological, metabolic, or mood disorders, were pregnant and/or nursing, or were unable to adhere to an 8-week supplement intervention. Furthermore, participants could not be regular users of anti-inflammatory medications or medications metabolized by the liver, nor could they be using sleep aids or sleep medications. Participants were excluded if they received the COVID-19 vaccination or were diagnosed with COVID-19 within three weeks of the initial visit. All available samples were used for this study. Prior to their involvement, all participants provided informed consent in accordance with the Declaration of Helsinki, and the protocol was approved was approved by the Institutional Review Board at the University of Northern Colorado (Protocol Number 2005001624A002, approved on 19 June 2020. This clinical trial was registered with clinicaltrials.gov (clinicaltrials.gov ID: NCT04881539. CBD, Immune Function, and Neural Health).